Clinical and Gene Analysis of Fatty Acid Oxidation Disorders Found in Neonatal Tandem Mass Spectrometry Screening

References

• Alfares A, Alfadhel M, Mujamammi A, et al. Proteomic and molecular assessment of the common Saudi variant in ACADVL gene through mesenchymal stem cells. Front Cell Dev Biol. 2020;7:365. doi:10.3389/fcell.2019.00365
   PubMed Web of Science ®Google Scholar
• Yamada K, Shiraishi H, Oki E, et al. Open-label clinical trial of bezafibrate treatment in patients with fatty acid oxidation disorders in Japan. Mol Genet Metab Rep. 2018;15:55–63. doi:10.1016/j.ymgmr.2018.02.003
   PubMed Web of Science ®Google Scholar
• Merritt JL, MacLeod E, Jurecka A, et al. Clinical manifestations and management of fatty acid oxidation disorders. Rev Endocr Metab Disord. 2020;21(4):479–493. doi:10.1007/s11154-020-09568-3
   PubMed Web of Science ®Google Scholar
• Kang E, Kim YM, Kang M, et al. Clinical and genetic characteristics of patients with fatty acid oxidation disorders identified by newborn screening. BMC Pediatr. 2018;18(1):103. doi:10.1186/s12887-018-1069-z
   PubMedGoogle Scholar
• Maguolo A, Rodella G, Dianin A, et al. Diagnosis, genetic characterization and clinical follow up of mitochondrial fatty acid oxidation disorders in the new era of expanded newborn screening: a single centre experience. Mol Genet Metab Rep. 2020;24:100632. doi:10.1016/j.ymgmr.2020.100632
   PubMed Web of Science ®Google Scholar
• Yang Y, Wang L, Wang B, et al. Application of next-generation sequencing following tandem mass spectrometry to expand newborn screening for inborn errors of metabolism: a multicenter study. Front Genet. 2019;10:86. doi:10.3389/fgene.2019.00086
   PubMed Web of Science ®Google Scholar
• Irwin C, Mienie LJ, Wevers RA, et al. GC-MS-based urinary organic acid profiling reveals multiple dysregulated metabolic pathways following experimental acute alcohol consumption. Sci Rep. 2018;8(1):5775. doi:10.1038/s41598-018-24128-1
   PubMedGoogle Scholar
• Merritt JL, Norris M, Kanungo S. Fatty acid oxidation disorders. Ann Transl Med. 2018;6(24):473. doi:10.21037/atm.2018.10.57
   PubMed Web of Science ®Google Scholar
• Huang XW, Zhang Y. Newborn screening for fatty acid oxidation disorders. Chin J Pract Pediatr. 2019;34(1):11–14. doi:10.19538/j.ek2019010605
   Google Scholar
• Han L, Han F, Ye J, et al. Spectrum analysis of common inherited metabolic diseases in Chinese patients screened and diagnosed by tandem mass spectrometry. J Clin Lab Anal. 2015;29(2):162–168. doi:10.1002/jcla.21745
   PubMed Web of Science ®Google Scholar
• Yang XF, Liu GS, Yi B. Primary carnitine deficiency in two sisters with intractable epilepsy and reversible metabolic cardiomyopathy: two case reports. Exp Ther Med. 2020;20(5):118. doi:10.3892/etm.2020.9246
   PubMed Web of Science ®Google Scholar
• Ravindranath A, Pai G, Srivastava A, et al. Infant with hepatomegaly and hypoglycemia: a setting for fatty acid oxidation defects. Indian J Gastroenterol. 2017;36(5):429–434. doi:10.1007/s12664-017-0790-0
   PubMedGoogle Scholar
• Deswal S, Bijarnia-Mahay S, Manocha V, et al. Primary carnitine deficiency – a rare treatable cause of cardiomyopathy and massive hepatomegaly. Indian J Pediatr. 2017;84(1):83–85. doi:10.1007/s12098-016-2227-7
   PubMed Web of Science ®Google Scholar
• Baruteau J, Sachs P, Broué P, et al. Clinical and biological features at diagnosis in mitochondrial fatty acid beta-oxidation defects: a French pediatric study of 187 patients. J Inherit Metab Dis. 2013;36(5):795–803. doi:10.1007/s10545-012-9542-6
   PubMed Web of Science ®Google Scholar
• Yang RL, Tong F, Zheng J. Screening, diagnosis and treatment of primary carnitine deficiency. Chin J Pract Pediatr. 2019;34(1):14–18. doi:10.19538/j.ek2019010606
   Google Scholar
• Li FY, El-Hattab AW, Bawle EV, et al. Molecular spectrum of SLC22A5 (OCTN2) gene mutations detected in 143 subjects evaluated for systemic carnitine deficiency. Hum Mutat. 2010;31(8):E1632–E1651. doi:10.1002/humu.21311
   PubMed Web of Science ®Google Scholar
• Jun JS, Lee EJ, Park HD, et al. Systemic primary carnitine deficiency with hypoglycemic encephalopathy. Ann Pediatr Endocrinol Metab. 2016;21(4):226–229. doi:10.6065/apem.2016.21.4.226
   PubMedGoogle Scholar
• Magoulas PL, El-Hattab AW. Systemic primary carnitine deficiency: an overview of clinical manifestations, diagnosis, and management. Orphanet J Rare Dis. 2012;7:68. doi:10.1186/1750-1172-7-68
   PubMed Web of Science ®Google Scholar
• Choi JS, Yoo HW, Lee KJ, et al. Novel mutations in the CPT1A gene identified in the patient presenting jaundice as the first manifestation of carnitine palmitoyltransferase 1A deficiency. Pediatr Gastroenterol Hepatol Nutr. 2016;19(1):76–81. doi:10.5223/pghn.2016.19.1.76
   PubMedGoogle Scholar
• Borch L, Lund AM, Wibrand F, et al. Normal levels of plasma free carnitine and acylcarnitines in follow-up samples from a presymptomatic case of carnitine palmitoyl transferase 1 (CPT1) deficiency detected through newborn screening in Denmark. JIMD Rep. 2012;3:11–15. doi:10.1007/8904_2011_35
   PubMedGoogle Scholar
• Heiner-Fokkema MR, Vaz FM, Maatman R, et al. Reliable diagnosis of carnitine palmitoyltransferase type IA deficiency by analysis of plasma acylcarnitine profiles. JIMD Rep. 2017;32:33–39. doi:10.1007/8904_2016_564
   PubMedGoogle Scholar
• Gessner BD, Gillingham MB, Johnson MA, et al. Prevalence and distribution of the c.1436C→T sequence variant of carnitine palmitoyltransferase 1A among Alaska Native infants. J Pediatr. 2011;158(1):124–129. doi:10.1016/j.jpeds.2010.07.031
   PubMed Web of Science ®Google Scholar
• Tsuburaya R, Sakamoto O, Arai N, et al. Molecular analysis of a presymptomatic case of carnitine palmitoyl transferase I (CPT I) deficiency detected by tandem mass spectrometry newborn screening in Japan. Brain Dev. 2010;32(5):409–411. doi:10.1016/j.braindev.2009.03.004
   PubMed Web of Science ®Google Scholar
• Cui D, Hu YH, Shen D, et al. Clinical characteristics and gene mutation analysis of a child with carnitine palmitoyltransferase 1A deficiency. Chin J Med Genet. 2017;34(2):228–231. doi:10.3760/cma.j.issn.1003-9406.2017.02.017
   Google Scholar
• Lisyová J, Chandoga J, Jungová P, et al. An unusually high frequency of SCAD deficiency caused by two pathogenic variants in the ACADS gene and its relationship to the ethnic structure in Slovakia. BMC Med Genet. 2018;19(1):64. doi:10.1186/s12881-018-0566-0
   PubMedGoogle Scholar
• Maduemem KE. Medium-chain acyl-Coenzyme A dehydrogenase deficiency (MCADD): a cause of severe hypoglycaemia in an apparently well child. BMJ Case Rep. 2016;2016:bcr2016217538. doi:10.1136/bcr-2016-217538
   PubMedGoogle Scholar
• Yamada K, Kobayashi H, Bo R, et al. Clinical, biochemical and molecular investigation of adult- onset glutaric acidemia type II: characteristics in comparison with pediatric cases. Brain Dev. 2016;38(3):293–301. doi:10.1016/j.braindev.2015.08.011
   PubMed Web of Science ®Google Scholar
• Dai DL, Wen FQ, Zhou SM, et al. Clinical manifestations and genetic analysis of late-onset multiple acyl coenzyme A dehydrogenase deficiency in combined severe fatty liver. Chin J Med Genet. 2016;33(2):191–194. doi:10.3760/cma.j.issn.1003-9406.2016.02.014
   Google Scholar
• Niu DM, Chien YH, Chiang CC, et al. Nationwide survey of extended newborn screening by tandem mass spectrometry in Taiwan. J Inherit Metab Dis. 2010;33(Suppl 2):S295–S305. doi:10.1007/s10545-010-9129-z
   PubMedGoogle Scholar
• Han LS. Paying attention to screening, diagnosis and treatment of fatty acid oxidation disorders. Chin J Pract Pediatr. 2019;34(1):6–10. doi:10.19538/j.ek2019010604
   Google Scholar
• Xi J, Wen B, Lin J, et al. Clinical features and ETFDH mutation spectrum in a cohort of 90 Chinese patients with late-onset multiple acyl-CoA dehydrogenase deficiency. J Inherit Metab Dis. 2014;37(3):399–404. doi:10.1007/s10545-013-9671-6
   PubMed Web of Science ®Google Scholar
• Grünert SC. Clinical and genetical heterogeneity of late-onset multiple acyl-coenzyme A dehydrogenase deficiency. Orphanet J Rare Dis. 2014;9:117. doi:10.1186/s13023-014-0117-5
   PubMed Web of Science ®Google Scholar
• Olsen RK, Olpin SE, Andresen BS, et al. ETFDH mutations as a major cause of riboflavin-responsive multiple acyl-CoA dehydrogenation deficiency. Brain. 2007;130(Pt 8):2045–2054. doi:10.1093/brain/awm135
   PubMedGoogle Scholar
• Wang ZQ, Chen XJ, Murong SX, et al. Molecular analysis of 51 unrelated pedigrees with late-onset multiple acyl-CoA dehydrogenation deficiency (MADD) in southern China confirmed the most common ETFDH mutation and high carrier frequency of c.250G>A. J Mol Med. 2011;89(6):569–576. doi:10.1007/s00109-011-0725-7
   PubMed Web of Science ®Google Scholar
• Cotelli MS, Vielmi V, Rimoldi M, et al. Riboflavin-responsive multiple acyl-CoA dehydrogenase deficiency with unknown genetic defect. Neurol Sci. 2012;33(6):1383–1387. doi:10.1007/s10072-011-0900-1
   PubMed Web of Science ®Google Scholar
• Zhang RN, Qiu WJ, Ye J, et al. Clinical and biochemical characteristics in children and adults with multiple acyl-CoA dehydrogenase deficiency. J Clin Pediatr. 2012;30(5):446–449. doi:10.3969/j.issn.1000-3606.2012.05.014
   Google Scholar